Recently, SOMO and Wemos published their research into the extent of Dutch public funding for drug development, through donations, loans and/or investments. The publication, Overpriced, reveals that because no conditions are set on these investments, the Government loses its chance to curb subsequent high drug prices. SOMO and Wemos argue the need for European legislation to ensure affordable medicines and a public return on public investment.
Various national media outlets have covered the publication and Dutch politicians, Van Gerven (SP) and Ellemeet (GroenLinks), have used it to question the Minister for Medical Care and Sports, Bruno Bruins (VVD).
Want to know more? Read the full story here in Dutch.